INVO Bioscience, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K, filed on April 17, 2023, by INVO Bioscience, Inc. (Nasdaq: INVO), serves as a current report to announce the issuance of a press release regarding financial results for the period ended December 31, 2022. The filing itself does not contain the detailed financial data but references the press release as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1) and are not detailed in the body of this 8-K document.
Material Changes
No material changes versus prior periods are described in this filing. The document solely notifies investors of the availability of the annual results announcement.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and shall not be incorporated by reference into other Company filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in this summary document.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated April 17, 2023) for actual financial figures for the year ended December 31, 2022.
- Verify the company's current status as an emerging growth company (indicated as not applicable in this filing).
- Confirm the trading symbol (INVO) and exchange (Nasdaq Stock Market LLC).
- Note that the financial data in the press release is not incorporated by reference into this specific 8-K filing.